0001104659-21-075911.txt : 20210602
0001104659-21-075911.hdr.sgml : 20210602
20210602191841
ACCESSION NUMBER: 0001104659-21-075911
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210602
FILED AS OF DATE: 20210602
DATE AS OF CHANGE: 20210602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nichols Andrew John
CENTRAL INDEX KEY: 0001683749
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37467
FILM NUMBER: 21990800
MAIL ADDRESS:
STREET 1: C/O CATABASIS PHARMACEUTICALS, INC.
STREET 2: ONE KENDALL SQUARE, BLDG 1400E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CATABASIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001454789
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 HIGH STREET
STREET 2: 28TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-349-1971
MAIL ADDRESS:
STREET 1: 100 HIGH STREET
STREET 2: 28TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
tm2118270-11_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-06-02
0
0001454789
CATABASIS PHARMACEUTICALS INC
CATB
0001683749
Nichols Andrew John
C/O CATABASIS PHARMACEUTICALS, INC.
100 HIGH STREET, FLOOR 28
BOSTON
MA
02110
0
1
0
0
Chief Scientific Officer
Stock Option (right to buy)
2.87
2021-06-02
4
A
0
600000
0
A
2031-03-31
Common Stock
600000
600000
D
Represents the closing price of the common stock of Catabasis Pharmaceuticals, Inc. (the "Company") on April 1, 2021.
This option was granted on April 1, 2021 subject to the approval by the stockholders of the Company of an increase in the number of shares of common stock available under the Company's Amended and Restated 2015 Stock Incentive Plan ("Proposal No. 4") at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). Proposal No. 4 received the requisite approval at the Annual Meeting on June 2, 2021. The option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of April 1, 2021 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.
/s/ Andrew J. Nichols
2021-06-02